Skip to Main Content

The Role of Hepatic De Novo Lipogenesis (DNL) in the Pathogenesis of Hepatic Steatosis

Conditions

Children's Health | Diseases of the Digestive System - Liver

What is the purpose of this trial?

Why are they doing this study?

Being overweight and having too much fat in your liver isn’t good for you, so doctors need to study why this takes place so they can figure out how to treat it. We want to test whether de novo lipogenesis (DNL), which is the process by which fat is obtained by dietary intake of carbohydrates, is enhanced after consumption of a high carbohydrate meal and if this might be a consequence of the production from the gut bacteria of some molecules called short chain fatty acids. The short chain fatty acids are good for us, but when produced in excess they can increase the production of fat in the liver and cause obesity and fatty liver. So, we want to see how your body is handling the carbohydrates that you eat while you are here for the study.

  • Trial with
    American Heart Association
  • Start Date
    04/18/2016
  • End Date
    04/30/2023
Trial Image

For more information about this study, contact:

Brittany Galuppo

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8348

  • Last Updated
    06/22/2018
  • Study HIC
    #1604017607